Table 1.
Clinical characteristics of 881 survivors of childhood hematological malignancy treated at St. Jude Children’s Research Hospital
| Characteristic | N=881 |
|---|---|
| Age at diagnosis (years) | |
| Median (range) | 5.6(0.1-24.6) |
| Follow-up time (years) | |
| Median (range) | 15.4 (5.3-48.1) |
| Gender | |
| Male | 487 (55%) |
| Female | 394 (45%) |
| Patient Type | |
| HSCT Survivors | 215 (24%) |
| 5-10 year duration | 107 (50%) |
| >10 year survivors | 108 (50%) |
| Non-HSCT Survivors | 666 (76%) |
| 5-10 year duration | 91 (14%) |
| >10 year survivors | 575 (86%) |
| Diagnosis | |
| HSCT Survivors | |
| Acute Lymphoblastic Leukemia | 43 (20%) |
| Acute Myeloid Leukemia | 89 (41%) |
| Chronic Myeloid Leukemia | 30 (14%) |
| Hodgkin Lymphoma | 21 (10%) |
| Non-Hodgkin Lymphoma | 11 (5%) |
| Other | 21 (10%) |
| Non-HSCT Survivors | |
| 5-10 year duration | |
| Acute Lymphoblastic Leukemia | 67 (74%) |
| Acute Myeloid Leukemia | 23 (25%) |
| Other | 1 (1%) |
| >10 year survivors | |
| Acute Lymphoblastic Leukemia | 517 (90%) |
| Acute Myeloid Leukemia | 49 (9%) |
| Other | 9 (2%) |
| ITR-3 Score | |
| 1 (lowest intensity) | 6 (1%) |
| 2 | 228 (26%) |
| 3 | 304 (35%) |
| 4 (highest intensity) | 343 (39%) |